May 6, 2026 04:00PM
Apr 27, 2026 08:01AM
Apr 27, 2026 08:00AM
Apr 22, 2026 08:04AM
Apr 22, 2026 08:00AM
Apr 8, 2026 09:15AM
Apr 7, 2026 12:26PM Palvella Therapeutics names Kent Taylor sales chief
Apr 7, 2026 07:30AM
Mar 28, 2026 11:00AM
Mar 28, 2026 11:00AM
Mar 18, 2026 08:00AM
Mar 10, 2026 09:00AM
Mar 10, 2026 09:00AM
Mar 5, 2026 09:01AM Arcutis promotes Mas Matsuda to chief legal officer
Mar 5, 2026 09:00AM
Feb 25, 2026 04:00PM
Feb 24, 2026 09:15AM
Feb 2, 2026 08:00AM
Feb 2, 2026 08:00AM
Jan 12, 2026 08:10AM
Jan 12, 2026 08:00AM Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones
Dec 21, 2025 08:00PM
Nov 17, 2025 08:04AM
Nov 17, 2025 08:00AM
Nov 13, 2025 08:00AM
Nov 13, 2025 08:00AM
Nov 4, 2025 08:04AM
Nov 4, 2025 08:00AM Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology
Oct 30, 2025 09:15AM
Oct 30, 2025 08:03AM
Oct 30, 2025 08:00AM
Oct 28, 2025 08:34AM
Oct 28, 2025 08:30AM
Oct 24, 2025 08:00AM
Oct 24, 2025 08:00AM Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference
Oct 6, 2025 08:00AM
Oct 6, 2025 08:00AM
Sep 17, 2025 04:00AM
Sep 16, 2025 09:00AM
Sep 3, 2025 11:44AM
Sep 3, 2025 11:43AM
Sep 3, 2025 07:30AM Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer
Aug 6, 2025 04:00PM
Jul 31, 2025 07:00AM
Jun 26, 2025 08:00AM
Jun 10, 2025 08:00AM
Jun 6, 2025 08:00AM
Jun 3, 2025 06:55AM
May 22, 2025 02:16PM Arcutis Biotherapeutics (ARQT) ZORYVE Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older
May 22, 2025 02:12PM

323,573 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All